Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
BUSINESS
Lonsurf-Bevacizumab Combo Extends Survival in PIII Colorectal Cancer Trial
Taiho Pharmaceutical said on September 13 that its cancer drug Lonsurf (trifluridine + tipiracil) in combination with bevacizumab hit the primary endpoint of overall survival (OS) in a PIII study covering refractory metastatic colorectal cancer (mCRC).The company’s PIII study, SUNLIGHT,…
To read the full story
Related Article
- Taiho Bags Label Update for Lonsurf Combo Use with Bevacizumab
March 29, 2024
- Lonsurf-Bevacizumab Combo Approved in EU for Colorectal Cancer: Taiho
August 2, 2023
- Lonsurf-Bevacizumab Combo Nabs EU Panel Nod for Colorectal Cancer
June 27, 2023
- Lonsurf-Bevacizumab Combo Gets FDA’s Priority Review in Colorectal Cancer: Taiho
April 20, 2023
BUSINESS
- Kyowa Kirin Sees Flat H1 Revenue as Japan Slump Offsets Overseas Gains
August 1, 2025
- Otsuka Accelerates Pipeline Investment Centered on “Next 8” as Growth Drivers
August 1, 2025
- Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
August 1, 2025
- Daiichi Sankyo Plays Down Tariff Impact for FY2025, Eyes US Production Boost
August 1, 2025
- Leqembi’s April-June Sales at 23.1 Billion Yen: Eisai
August 1, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…